KPC Pharmaceuticals Inc
SSE:600422
KPC Pharmaceuticals Inc
Other Liabilities
KPC Pharmaceuticals Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
KPC Pharmaceuticals Inc
SSE:600422
|
Other Liabilities
ÂĄ289.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
22%
|
||
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Liabilities
ÂĄ22m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Liabilities
ÂĄ94.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Liabilities
ÂĄ42.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Liabilities
ÂĄ892.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
17%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Liabilities
ÂĄ26.8m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
KPC Pharmaceuticals Inc
Glance View
KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.
See Also
What is KPC Pharmaceuticals Inc's Other Liabilities?
Other Liabilities
289.1m
CNY
Based on the financial report for Sep 30, 2024, KPC Pharmaceuticals Inc's Other Liabilities amounts to 289.1m CNY.
What is KPC Pharmaceuticals Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
22%
Over the last year, the Other Liabilities growth was 6%. The average annual Other Liabilities growth rates for KPC Pharmaceuticals Inc have been 2% over the past three years , 7% over the past five years , and 22% over the past ten years .